Successful treatment of pyridoxine-unresponsive homocystinuria with betaine in pregnancy

Germaine Pierre, Paul Gissen, Anupam Chakrapani, Anita McDonald, Maryanne Preece, Joy Wright
Journal of inherited metabolic disease 2006 29(5):688-689

Bibliography

PubMed
PMID 16972179
DOI
10.1007/s10545-006-0352-6
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignIndexed case report; abstract unavailable
ModelHuman participants
SampleNot available in the indexed record
InterventionFormulation and dose require the original full report
DurationNot available in the indexed record
EndpointsHistorical or clinical context

What the study showed, in plain terms

Published in 2006, this source examined prescription betaine and inherited metabolic disorders. It is retained for source traceability. Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

The indexed record verifies the publication and citation, but supplies no abstract. A quantitative effect or complete treatment result is not established from this record alone.

Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.

Continue with TMG Data Center

Continue with TMG, Methylation and MTHFR: Understanding the Evidence

Key findings

  • The indexed record verifies the publication and citation, but supplies no abstract.
  • A quantitative effect or complete treatment result is not established from this record alone.
  • The recorded outcome domains were Historical or clinical context.

What this study can and cannot tell us

  • Abstract unavailable in PubMed and no accessible full report was verified for this summary. The paper title is not treated as sufficient evidence of efficacy, dose, safety or causality.
  • Source basis: Bibliographic data only; no abstract available. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Prospective associations of maternal betaine status with offspring weight and body composition at birth: the Growing Up in Singapore Towards healthy Outcomes (GUSTO) cohort study
Linde van Lee et al. · The American journal of clinical nutrition · 2016
Tier 4
Association of Maternal and Cord Blood Choline and Betaine Concentrations with Birthweight: A Prospective Mother-Infant Cohort Study
Sumiya Aihemaitijiang et al. · Nutrients · 2026
Tier 4
Maternal Betaine and Methylation Potential during Pregnancy Are Associated with Child Growth at Birth and Early Childhood: Results of the Chilean Maternal & Infant Cohort Study-II
Isis Trujillo-González et al. · The Journal of nutrition · 2026
Tier 4
Early second trimester maternal plasma choline and betaine are related to measures of early cognitive development in term infants
Brian T F Wu et al. · PloS one · 2012
Tier 2
First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders
Giorgia Olivieri et al. · Journal of inherited metabolic disease · 2026
Tier 2
Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency
Andrew A M Morris et al. · Journal of inherited metabolic disease · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology